Salt Lake City, UT – October 24, 2019 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Flagg Flanagan, Chairman and CEO, will present at the 2019 Musculoskeletal New Ventures Conference on Tuesday, October 29, 2019 at 9:30 a.m. CDT.
The event, now in its 17th year, is hosted by MB Venture Partners and Memphis Bioworks Foundation, and brings together surgeons, venture capitalists, industry leaders and researchers to share information on the latest in musculoskeletal research. MNVC 2019 will be held on October 29 – 30, 2019 at the FedEx Institute of Technology at the University of Memphis.
About DiscGenics
DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics believes it has a unique opportunity to harness the restorative potential of the human body to heal millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue, known as Discogenic Cells, to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease.